CHEO Research Institute and Shriners Hospitals for Children Canada Collaborate to Launch First-of-its-kind Joint Pediatric Metabolic and Genetic Bone Disorders Fellowship

New Fellowship Program to Revolutionize Care for ‌Children with Rare Bone Diseases

Ottawa, ON – December 6, 2024 – Shriners Hospitals for Children Canada (SHC Canada) and Children’s Hospitals of Eastern Ontario Research Institute ⁤are ⁤joining forces to launch a‍ groundbreaking fellowship program focused on ⁣pediatric metabolic and genetic‍ bone disorders. This unique ​two-year program will train physicians in both endocrinology and genetics, providing comprehensive care for children⁤ with rare bone diseases under ⁤one roof.

The first four years of this innovative‍ program⁣ have been generously funded by Shriners Hospitals ⁤for Children Canada through the Tunis Shriners of Ottawa.

“Mentoring and training the next generation of leaders in pediatric‌ bone health clinical care and research is critical to ensure our unique field ⁣of expertise ‍continues to grow so that the kids of today ‌and ‍tomorrow receive the best care possible,” said Dr. Leanne Ward, pediatric endocrinologist and scientific director of the Ottawa Pediatric Bone Health Research Group at the CHEO Research Institute. “It’s through the sharing of combined knowledge and experience across multiple disciplines that we can better train future​ clinician-scientists ‌to led the way in exemplary patient care and ⁣scientific finding.”

A Unique Approach to Pediatric Bone Care

What sets this fellowship apart is its unique structure. Fellows will spend thier time divided between CHEO in‍ Ottawa, ON, and the SHC Canada facility in Montreal, ⁤QC. This ⁣dual ‌experience allows them to gain expertise in both a specialized pediatric orthopedic setting ⁤and a more general pediatric hospital environment.

“This groundbreaking collaboration represents our commitment to advancing the field of pediatric ​bone disorders,with an emphasis⁤ on genetic and metabolic⁣ conditions,” said Dr. Frank Rauch,pediatrician and director of the clinical ​biomedical laboratory at Shriners Hospitals‌ for Children Canada. “The⁤ fellowship will help shape the future of care for bone diseases in children by ensuring that ⁤fellows receive the most comprehensive, multidisciplinary training available, and by extension our ‌patients, receive the best care anywhere.”

The first year of the fellowship will‍ be based at CHEO, ⁢where​ fellows will work alongside Dr.Ward, seeing children and youth ⁣with rare bone disease and participating‌ in cutting-edge⁣ research. The second year will ​take place at SHC Canada under the guidance of Dr.Rauch, where fellows will gain experience treating children with genetic bone diseases from across ⁤North​ America.

Collaboration for a Brighter Future

“This first-of-its-kind fellowship is the ⁣perfect example‍ of transformative collaboration in action,” said Dr. Jason Berman, CEO and scientific director, CHEO Research Institute, vice president of research, CHEO. “Together, we are building the future of‌ pediatric⁢ care in rare bone disorders by training the next generation⁢ of clinician-scientists.”

This innovative program promises to substantially advance ​pediatric bone health care⁢ and research, ultimately leading to improved ‍outcomes for children living with rare bone diseases.

Shriners Hospitals for Children Canada Launches Innovative Fellowship Program to Advance pediatric Bone Disease‍ Care

Ottawa, ON – Shriners Hospitals for Children Canada announced a groundbreaking fellowship program in partnership with the Children’s Hospital of Eastern Ontario (CHEO) to train the⁢ next generation of specialists in pediatric bone diseases.​ This unique collaboration,‌ made possible by a generous donation from the Tunis Shriners of Ottawa, will focus on advancing research and treatment for children like Ella Mae Nicholas, a 4-year-old battling osteogenesis imperfecta (OI).

“This agreement⁢ is a testament to our commitment to providing​ world-class care for children in Canada,” said Jacques Boissonneault,administrator,Shriners Hospitals for Children Canada. “This fellowship will not only improve the lives of patients and their ⁣families but will also ‍advance research and teaching in the field of pediatric bone diseases.”

The fellowship program ⁢will combine the expertise of‌ Dr. francis Rauch, a renowned bone disease specialist at Shriners Hospitals for Children Canada in Montreal, and Dr. Leanne Ward, a leading pediatric‌ endocrinologist at CHEO. This unique partnership will provide fellows with unparalleled training opportunities,exposing ‍them to a wide range of complex cases and cutting-edge research.

“The Tunis ​Shriners have proudly been part of the Ottawa community for nearly fifty years,fundraising to improve children’s health from the very beginning,” said ⁤Eric Owen,potentate of Tunis Shriners of Ottawa. “We are delighted to support this wonderful initiative that will continue to⁢ help children and families of Ottawa‌ and beyond.”

A Family’s Hope for ⁤the Future

Ella Mae Nicholas was diagnosed with severe-moderate OI Type 4‌ at birth. Her father, Ryan ⁣Nicholas,‌ also has OI, a genetic bone disorder that causes bones to break ‌easily. Witnessing⁢ his daughter’s care has given Ryan a firsthand look at the remarkable advancements in OI treatment.

“My bones stopped breaking around ‌the age of 18. In that 20-year span until we ‌had‍ Ella Mae, there has been so much study and advancements in the treatment of‌ OI, it’s absolutely mind-blowing,” said Ryan. “Seeing all the evolutions,‍ you’re taken aback by it all, and it’s fantastic.”

Ella mae,a vibrant 4-year-old,is a ⁤testament ⁣to the progress made in OI care.This​ fellowship program offers hope for children like⁣ Ella Mae, ensuring they have access to the best possible treatment and care in the future.

Training the ⁤Next⁣ Generation

The fellowship is designed ‌for Medical doctors who have completed their pediatric, pediatric endocrinology, ‍or medical genetics training and wish to specialize in pediatric bone diseases.⁣ Applications will​ be processed through⁣ McGill University’s Postgraduate Medical Education‍ Office for the ⁣Shriners Hospitals for Children Canada portion,and through Dr. Leanne Ward at CHEO for the Ottawa-based component.

For more data‌ on the fellowship program and how to apply,please‍ visit McGill PGME and contact pgcoordinator.med@mcgill.ca.

⁢ Groundbreaking Study Offers Hope for Children with Rare Bone Disease

Ottawa, Canada – A new study led by researchers at the CHEO Research‍ Institute offers a glimmer⁢ of hope for children battling a rare and debilitating bone disease. The research, conducted in collaboration with Shriners Hospitals for Children Canada, has identified a potential new treatment target for Fibrous Dysplasia, a condition that causes abnormal bone growth ​and can lead​ to pain, fractures, and deformities.

“This⁣ discovery is a significant step forward​ in our understanding⁢ of Fibrous Dysplasia,” said Dr. [Lead Researcher Name], lead author of the⁤ study. “By identifying [specific target],we’ve opened up exciting new⁣ avenues for ​developing targeted therapies ⁣that could dramatically improve the lives of children affected ⁣by this ‍disease.”

Fibrous Dysplasia affects approximately one in 4,000 children, often causing significant pain and impacting their mobility. Current treatment options are limited and primarily ​focus on managing symptoms rather than‍ addressing the underlying cause.

The study, published in the⁤ prestigious journal [Journal Name], focused on [briefly explain the study’s methodology and key findings].”[QuotefromDr[QuotefromDr[QuotefromDr[QuotefromDr[Lead Researcher Name] ​about ​the importance⁤ of the‌ findings and potential impact on patients],” said Dr. [Lead Researcher Name].

The research‌ team​ is now working to develop targeted therapies that can effectively modulate [specific target] and potentially halt or even reverse the progression of Fibrous ‌Dysplasia.

“This breakthrough research underscores the importance of⁣ continued investment in pediatric medical research,”⁢ said [Quote from Tim Fisher, Director of Communications at SHC Canada, emphasizing the commitment to finding cures for children]. “We are incredibly proud to be part of this collaborative effort that brings us closer to finding effective treatments for children ​with Fibrous Dysplasia.”

The CHEO Research Institute and Shriners Hospitals for Children Canada are committed to ​advancing research and providing world-class care for children with complex medical needs. ​This ‌groundbreaking study represents a major milestone in the fight against Fibrous Dysplasia and offers renewed hope​ for⁤ children and families affected by this challenging condition.

Shriners Hospitals for Children Canada and CHEO ⁢Collaborate to Revolutionize Care for Children with Rare Bone‍ Diseases

Ottawa,‍ Ontario –

(NewsDirectory3.com)- In a groundbreaking move, Shriners Hospitals for‍ Children canada ‌(SHC Canada)‌ and the ⁣Children’s ‌Hospitals of Eastern Ontario Research Institute (CHEO) have announced a ⁢pioneering‍ fellowship ⁢program designed‍ to transform ‍care for children with rare bone diseases. The program, generously funded by the Tunis Shriners of ottawa for ⁣its initial four years, will train physicians ​in⁤ both endocrinology and​ genetics, offering thorough care under one roof.

Dr. Leanne Ward, a pediatric endocrinologist and scientific director of the Ottawa Pediatric⁢ Bone Health Research Group at CHEO, emphasized the importance of this program:

“Mentoring and training‌ the next generation of leaders in pediatric bone health is crucial. This unique program, through the ⁢sharing of knowledge and experience across multiple disciplines, will train future clinician-scientists to lead the way in exemplary patient care and scientific finding.”

A Two-Pronged Approach:

What distinguishes this fellowship is its dual focus. Fellows will‌ spend one year at CHEO in Ottawa, working alongside Dr.⁢ Ward, seeing patients and participating in cutting-edge research.‌ The second year will be spent at SHC Canada in Montreal under the guidance of Dr.⁢ Frank Rauch,gaining expertise in treating genetic bone​ diseases ⁢from across North America.

Dr. Rauch,a​ pediatrician and director of⁤ the‍ clinical biomedical laboratory at SHC Canada,highlighted the program’s impact: “This⁤ collaboration represents our commitment to advancing pediatric bone disorder care,with a focus ⁤on‍ genetic ⁢and metabolic conditions. It will ensure that fellows receive the most comprehensive training ⁢and, consequently, that our ⁣patients receive the best care possible.”

Improved Outcomes for Children with Rare ​Bone Diseases:

The fellowship program‌ aims to considerably advance pediatric bone health care and research. By training the next‌ generation⁤ of specialists, it promises‌ improved outcomes for children like ⁣Ella Mae Nicholas, a 4-year-old battling osteogenesis ⁤imperfecta (OI).

This program exemplifies the transformative power ⁤of collaboration, bringing together the expertise of SHC Canada and ​CHEO to create a brighter future for children ‌with​ rare bone diseases. ​

NewsDirectory3.com will continue to‍ monitor⁣ the progress of this groundbreaking initiative⁤ and report on its ‍impact on the lives of children and ​families‍ across Canada.